Kezar’s complementary therapeutic platforms harness key regulators of cellular function and inhibit multiple drivers of disease, enabling the potential for significant clinical impact in the most difficult-to-treat diseases.
Both of Kezar's clinical candidates, KZR-616 and KZR-261, are first-in-class small molecule drugs. As a selective inhibitor of the immunoproteasome, KZR-616 has demonstrated broad immunomodulatory activity and has the potential to be an important new treatment for patients with autoimmune disease. By targeting the activity of the Sec61 translocon, KZR-261 blocks many key proteins from entering the protein secretion pathway. This results in several validated oncology targets being blocked with a single small molecule and speaks to the broad potential of this uniquely powerful new mechanism in both solid and hematologic tumor types.
KZR-261 is the first clinical candidate from our protein secretion program and a broad-spectrum anti-tumor agent that acts through direct interaction and inhibition at the Sec61 translocon.View Candidate